| |
著者: Strezova A, Diez-Domingo J, Al Shawafi K, Tinoco JC, Shi M, Pirrotta P, Mwakingwe-Omari A; Zoster-049 Study Group.
雑誌名: Open Forum Infect Dis. 2022 Oct;9(10):ofac485. doi: 10.1093/ofid/ofac485. Epub 2022 Oct 23.
Abstract/Text
Approximately 10 years after vaccination with the recombinant zoster vaccine (RZV), an interim analysis of this follow-up study of the ZOE-50/70 trials demonstrated that efficacy against herpes zoster remained high. Moreover, the safety profile remained clinically acceptable, suggesting that the clinical benefit of the RZV in ≥50-year-olds is sustained up to 10 years.
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
PMID 36299530 Open Forum Infect Dis. 2022 Oct;9(10):ofac485. doi: 10.1093/ofid/ofac485. Epub 2022 Oct 23.
|
